Melanoma & Skin Cancers at CIOC 2027

Skin cancers, including melanoma and non-melanoma types, are increasingly recognized as a major public health concern due to their rising incidence and potential for metastasis. Melanoma & Skin Cancers require early detection, accurate diagnosis, and a comprehensive, multidisciplinary approach to treatment. Advances in dermoscopy, imaging technologies, and molecular profiling have enhanced the identification of high-risk lesions and informed personalized treatment strategies. Therapeutic approaches often combine surgical excision, immunotherapy, targeted therapy, and, in select cases, radiation therapy to optimize outcomes. Collaboration among dermatologists, surgical oncologists, medical oncologists, and supportive care teams is essential to address both clinical outcomes and the overall quality of life for patients.

The landscape of Melanoma & Skin Cancers is rapidly evolving with the integration of novel immunotherapies, checkpoint inhibitors, and targeted agents, significantly improving survival for patients with advanced disease. Molecular diagnostics and biomarker testing allow clinicians to select therapies most likely to achieve favorable responses, while adjuvant and neoadjuvant strategies help reduce recurrence risk. Supportive care, patient education, and survivorship planning are critical for managing side effects and promoting long-term well-being. By combining precision medicine, innovative therapies, and multidisciplinary care, melanoma and skin oncology continues to advance, offering patients more effective, individualized, and durable treatment options while enhancing overall quality of life.